natgillin/translations-raw huggingface dataset:
If creatinine clearance is ≤ 30 ml/ minute/ 1.73 m2 or the serum creatinine concentration is ≥ 175 µmol/ l, the maximum daily intravenous dose is 400 mg.
Če je kreatininski očistek ≤ 30 ml/ min/ 1, 73 m2 ali če je koncentracija kreatinina v serumu ≥ 175 µmol/ l, je največji dnevni intravenski odmerek 400 mg.
In patients on haemodialysis or CAPD, the maximum daily intravenous dose is also 400 mg.
Pri bolnikih na hemodializi ali KAPD je dnevni intravenski odmerek prav tako 400 mg.
On the dialysis days, the dose is given after the haemodialysis session.
Na dneve, ko je bolnik na dializi, se odmerek daje po hemodializi.
In case of impaired hepatic function it is not necessary to adjust the dosage.
Pri okvarjenem delovanju jeter odmerka ni treba prilagajati.
Dose adjustment according to renal function.
Odmerek je treba prilagoditi glede na ledvično okvaro.
Acute lower respiratory tract infections caused by Pseudomonas aeruginosa in children and adolescents (5-17
Akutne okužbe spodnjih dihal, ki jih povzroča bakterija Pseudomonas aeruginosa pri otrocih in mladostnikih (od 5 do 17 let) s cistično fibrozo:
Twice daily intravenous administration of 15 mg/ kg bodyweight, or 10 mg/ kg bodyweight three times daily (maximum of 1200 mg per day).
Intravensko odmerjanje 15 mg/ kg telesne mase dvakrat na dan ali 10 mg/ kg telesne mase trikrat na dan (največ 1200 mg na dan).
Twice daily intravenous administration of 15 mg/ kg bodyweight, or 10 mg/ kg bodyweight three times daily (maximum of 1200 mg per day), then twice daily oral administration.
Intravensko odmerjanje 15 mg/ kg telesne mase dvakrat na dan ali 10 mg/ kg telesne mase trikrat na dan (največ 1200 mg na dan), nato pa peroralno odmerjanje dvakrat na dan.
The recommended duration of treatment is 10 - 14 days.
Priporočeno trajanje zdravljenja je 10- 14 dni.
The dosage in children with impaired renal and/ or hepatic function has not been investigated.
Odmerjanja pri otrocih z okvarjenim delovanjem ledvic in/ ali jeter niso raziskovali.
For information on mixing with other solutions: see sections 6.2 and 6.6.
Za informacije o mešanju z drugimi raztopinami glejte poglavji 6. 2 in 6. 6.
Generally, acute and chronic infections (e. g. osteomyelitis and prostatitis, etc), where the causative organism is known to be sensitive to ciprofloxacin, should be treated for at least three days after the signs and symptoms of the infection have disappeared.
Na splošno velja, da je treba akutne in kronične okužbe (npr. osteomielitis in prostatitis), pri katerih je znano, da je povzročitelj občutljiv na ciprofloksacin, zdraviti vsaj še tri dni po izginotju znakov in simptomov okužbe.
Ciprofloxacin Hikma is contraindicated in: • patients with a hypersensitivity to ciprofloxacin, quinoline carboxylic acid derivatives or to any of the excipients
Zdravilo Ciprofloxacin Hikma je kontraindicirano pri: • bolnikih, ki so preobčutljivi za ciprofloksacin, derivate kinolin- karboksilne kisline ali katero koli pomožno snov; • otrocih, mlajših od 5 let.
With regard to the safety and use of ciprofloxacin in children, see also section 4.4 • children and growing adolescents except for the treatment of acute pulmonary exacerbations of cystic fibrosis in children aged 5 to 17 years. • pregnancy and lactation • patients with a history of tendon disorder related to fluoroquinolone administration • Concurrent administration of ciprofloxacin and tizanidine
Za informacije o varnosti in uporabi ciprofloksacina pri otrocih, glejte tudi poglavje 4. 4; • otrocih in odraščajočih mladostnikih, razen za zdravljenje akutnih pulmonalnih eksacerbacij cistične fibroze pri otrocih, starih od 5 do 17 let; • nosečnosti in dojenju; • bolnikih z okvaro kit, povezano z uporabo fluorokinolonov v anamnezi; • sočasni uporabi ciprofloksacina in tizanidina.
Renal and urinary system:
Sečila:
Patients with a family history of or actual defects in glucose-6-phosphate dehydrogenase activity are prone to haemolytic reactions with quinolones, and so ciprofloxacin should be used with caution in these patients.
Bolniki z okvaro delovanja glukoze- 6- fosfat dehidrogenaze v družinski anamnezi so nagnjeni k hemolitičnim reakcijam na kinolone, zato je treba ciprofloksacin pri njih uporabljati previdno.
In patients with epilepsy or other lesions of the central nervous system (e. g. reduced convulsion threshold, a history of epileptic seizures, diminished cerebral blood flow, changes in brain structure or stroke), ciprofloxacin is only to be used after carefully weighing the benefits against the risk, because the possibility of central nervous side effects puts these patients at increased risk.
Pri teh bolnikih se namreč poveča nevarnost pojava stranskih učinkov, povezanih z vplivom zdravila na osrednje živčevje.
Since ciprofloxacin is associated with very rare cases of QT prolongation (see section 4.8) caution should be exercised when treating patients at risk for torsade de pointes arrhythmia.
Ciprofloksacin je povezan z zelo redkimi primeri podaljšanja intervala QT (glejte poglavje 4. 8), zato je pri zdravljenju bolnikov s tveganjem za aritmijo "torsade de pointes", potrebna previdnost.
Therefore, the use of ciprofloxacin in children is generally not recommended, except for cystic fibrosis patients (see section 4.1).
Zato njegova uporaba pri otrocih na splošno ni priporočena, razen za zdravljenje bolnikov s cistično fibrozo (glejte poglavje 4. 1).
Gastrointestinal tract:
Prebavila:
9 If there is any indication of tendinitis (e. g. painful swelling) the administration of ciprofloxacin or other fluoroquinolones must immediately be discontinued, the affected extremity should not be strained and a physician must be consulted.
Če se pojavijo kakršni koli znaki tendinitisa (npr. boleča oteklina), je treba zdravljenje s ciprofloksacinom ali drugimi fluorokinoloni takoj ustaviti, prenehati je treba telesno dejavnost in se posvetovati z zdravnikom.
Therefore, it is recommended to avoid prolonged exposure to sunlight or UV light during treatment with ciprofloxacin.
Zato je treba bolnikom svetovati, naj se med zdravljenjem s ciprofloksacinom izogibajo daljšemu izpostavljanju sončni svetlobi ali UV- svetlobi.
Hypersensitivity:
10 Preobčutljivost:
Anaphylactic/ anaphylactoid reactions can in very rare cases develop into life-threatening shock, sometimes even after the first administration of ciprofloxacin.
Anafilaktične/ anafilaktoidne reakcije lahko v redkih primerih povzročijo smrtno nevarni šok, včasih že po prvem odmerku ciprofloksacina.
Ciprofloxacin Hikma contains 15.4 mmol (354 mg) sodium per 100 ml of solution for infusion.
Zdravilo Ciprofloxacin Hikma vsebuje 15, 4 mmol (354 mg) natrija na 100 ml raztopine za infundiranje.
Probenecid Probenecid inhibits the renal excretion of ciprofloxacin resulting in an increase in the plasma concentration of ciprofloxacin.
Probenecid Probenecid zavira izločanje ciprofloksacina skozi ledvice, kar povzroči povečanje koncentracije ciprofloksacina v plazmi.
CYP1A2 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, tacrine, ropinirol, tizanidine).
CYP1A2 Ciprofloksacin zavira encim CYP1A2 in zato lahko poveča serumske koncentracije sočasno uporabljenih snovi, ki jih ta encim presnavlja (npr. teofilin, klozapin, takrin, ropinirol, tizanidin).
Other xanthine derivatives On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.
Drugi derivati ksantina Med sočasno uporabo ciprofloksacina in kofeina ali pentoksifilina (okspentifilina) so poročali o povečanih koncentracijah ksantinskih derivatov.
10 Simultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum levels of phenytoin such that monitoring of drug levels is recommended.
Fenitoin Sočasna uporaba ciprofloksacina in fenitoina lahko povzroči takšno zvišanje ali znižanje ravni fenitoina v serumu, da se priporoča spremljanje ravni zdravila v serumu.
Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin potentially leading to increased plasma levels of methotrexate.
Metotreksat Pri sočasni uporabi ciprofloksacina in metotreksata lahko pride do zaviranja tubulnega transporta metotreksata, zaradi česar se njegova koncentracija v plazmi zveča.
Cyclosporine Following concomitant administration of ciprofloxacin and cyclosporine a transient increase of the serum creatinine concentration has been observed in separate cases.
Ciklosporin Po sočasni uporabi ciprofloksacina in ciklosporina so v posameznih primerih opazili prehodno povečanje koncentracije kreatinina v serumu.
Oral anticoagulants (e. g. warfarin) Ciprofloxacin, like other quinolones, may enhance the effect of coumarin derivates including warfarin.
Peroralni antikoagulansi (npr. varfarin) Ciprofloksacin, kot drugi kinoloni, lahko okrepijo učinek derivatov kumarina, vključno z varfarinom.
Glibenclamide When used simultaneously, ciprofloxacin may, in certain cases, increase the effect of glibenclamide (hypoglycaemia).
11 Glibenklamid Pri sočasni uporabi lahko ciprofloksacin v nekaterih primerih poveča učinek glibenklamida (hipoglikemija).
NSAIDs Animal trials have shown that the concurrent administration of very high doses of fluoroquinolones and certain NSAIDs (but not acetylsalicylic acid) may provoke convulsions.
Nesteroidna protivnetna zdravila Preskušanja na živalih so pokazala, da lahko sočasna uporaba zelo velikih odmerkov fluorokinolonov in nekaterih nesteroidnih protivnetnih zdravil (vendar ne acetilsalicilne kisline) izzove konvulzije.
Mexiletine Simultaneous administration of ciprofloxacin and mexiletine can lead to increased plasma concentrations of mexiletine.
Meksiletin Sočasna uporaba ciprofloksacina in meksiletina lahko poveča koncentracijo meksiletina v plazmi.
Premedicants It is recommended that opiate premedicants, (e. g. papaveretum) or opiate premedicants used with anticholinergic premedicants, (e. g. atropine or hyoscine) are not used concomitantly with ciprofloxacin, as the serum levels of ciprofloxacin are reduced.
Premedikacija Priporočeno je, da se opiatna premedikacija (npr. papaveretum) ali opiatna premedikacija, ki se uporablja z antiholinergično premedikacijo (npr. atropin ali hioscin), ne uporablja sočasno s ciprofloksacinom, ker se ravni ciprofloksacina znižajo.
Co-administration of ciprofloxacin and benzodiazepine premedicants has been shown not to affect ciprofloxacin plasma levels.
Pokazali so, da sočasna uporaba ciprofloksacina in benzodiazepinskih premedikantov ne vpliva na ravni ciprofloksacina v plazmi.
Pregnancy Use during pregnancy is contraindicated.
Nosečnost Uporaba med nosečnostjo je kontraindicirana.
In juvenile and prenatal animals exposed to quinolones effects on immature cartilage have been observed (see section 5.3).
Pri neodraslih in prenatalnih živalih, izpostavljenih kinolonom, so opazili učinke na hrustanec (glejte poglavje 5. 3).
Since the risks for humans are unknown Ciprofloxacin Hikma must not be administered during pregnancy (see section 4.3).
Tveganje za človeka ni znano, zato se zdravilo Ciprofloxacin Hikma med nosečnostjo ne sme uporabljati (glejte poglavje 4. 3).
11 Lactation:
Dojenje:
Due to the risk of arthropathy and other potentially severe toxicity in the infant, ciprofloxacin is contraindicated during lactation (see section 4.3).
Zaradi tveganja za artropatijo in druge hude toksične učinke na novorojenca je ciprofloksacin med dojenjem kontraindiciran (glejte poglavje 4. 3).
Adverse reactions have been reported in 5-14% of patients receiving ciprofloxacin.
O neželenih reakcijah so poročali pri 5- 14% bolnikov, ki so prejemali ciprofloksacin.
Very common (≥ 1/ 10) Common (≥ 1/ 100 to < 1/ 10) Uncommon (≥ 1/ 1 000 to < 1/ 100) Rare (≥ 1/ 10,000 to < 1/ 1,000) Very rare (< 1/ 10,000), not known (cannot be estimated from the available data)
Zelo pogosti (≥ 1/ 10) Pogosti (≥ 1/ 100 do < 1/ 10) Občasni (≥ 1/ 1000 do < 1/ 100) Redki (≥ 1/ 10. 000 do < 1/ 1000) Zelo redki (< 1/ 10000), neznano (iz razpoložljivih podatkov ni mogoče oceniti)
Uncommon: moniliasis
Občasni: kandidoza
Rare: leukopenia (granulocytopenia), anaemia, leukocytosis, thrombocytopenia, thrombocytemia (thrombocytosis).
12 Redki: levkopenija (granulocitopenija), anemija, levkocitoza, spremenjene vrednosti protrombina, trombocitopenija, trombocitemija (trombocitoza).
Rare: hyperglycaemia.
Redki: hiperglikemija.
Rare: disturbed vision, diplopia, chromatopsia.
Redki: motnje vida, diplopija, kromatopsija.
12 Ear and labyrinth disorders:
Ušesne bolezni, vključno z motnjami labirinta:
Rare: tinnitus, transient hearing loss (particularly high frequencies).
Redki: tinitus, prehodna izguba sluha (zlasti visokih frekvenc).
(thrombo) phlebitis.
(trombo) flebitis.
Rare: dyspnoea, laryngeal oedema.
Redki: dispneja, laringealni edem.
Skin and subcutaneous tissue disorders:
13 Bolezni kože in podkožja:
Common: rash.
Pogosti: izpuščaj.
Very rare: erythema nodosum, erythema multiforme (minor), Stevens-Johnson syndrome, epidermal necrolysis (Lyell Syndrome), petechia.
Zelo redki: nodozni eritem, multiformni eritem (manjši), Stevens- Johnsonov sindrom, epidermalna nekroliza (Lyellov sindrom), petehija.
13 Very rare: increment of amylase/ lipase levels.
Zelo redki: zvišanje ravni amilaz/ lipaz.
Very rare: asthenia, a transient impairment of kidney function to transient renal failure, photosensitivity (see Section 4.4).
Zelo redki: astenija, prehodna okvara delovanja ledvic do prehodne ledvične odpovedi, fotosenzitivnost (glejte poglavje 4. 4).
Adequate hydration must be ensured.
Bolnika je treba pozorno spremljati in mu nuditi simptomatsko zdravljenje ter podporne ukrepe. zagotoviti je treba ustrezno hidracijo.
At haemodialysis or peritoneal dialysis only a modest amount of ciprofloxacin (less than 10%) is eliminated.
S hemodializo ali peritonealno dializo se izloči le majhna količina ciprofloksacina (manj kot 10%).
Antibacterial quinolones, ATC code:
Farmakoterapevtska skupina: kinolonske protimikrobne učinkovine, oznaka ATC:
The enzyme DNA-gyrase plays a crucial role in this process.
Pri tem ima DNA- giraza ključno vlogo.
Ciprofloxacin inhibits DNA-gyrase, resulting in inhibition of DNA synthesis.
Ciprofloksacin zavira DNA- girazo, kar povzroči zaviranje sinteze DNA.
Resistance to ciprofloxacin develops in stages through genomic mutations (multiple-step type).
14 Rezistenca za ciprofloksacin se razvija postopno skozi genomske mutacije (po korakih).
Transferable plasmid-mediated quinolone resistance associated with qnr has been detected in quinolone-resistant clinical strains of E. coli and Klebsiella spp.
Prenosljivo rezistenco za kinolone, povezano z genom qnr, ki se prenaša s plazmidi, so odkrili pri sevih bakterij E. coli in Klebsiella spp, rezistentnih na kinolone.
As a result of its mechanism of action, ciprofloxacin does not show cross-resistance with other important, chemically different groups of substances such as beta-lactam antibiotics, aminoglycosides, tetracyclines, macrolides and polypeptides, sulphonamides, trimethoprim and nitrofurantoine.
Zaradi svojega načina delovanja ciprofloksacin nima navzkrižne rezistence z drugimi pomembnimi, kemijsko različnimi skupinami zdravil, kot so beta - laktamski antibiotiki, aminoglikozidi, tetraciklini, makrolidi in polipetidi, sulfonamidi, trimetoprim in nitrofurantoin.
Development of resistance to ciprofloxacin and other fluoroquinolones has been observed in staphylococci, especially methicillin- resistant S. aureus, P. aeruginosa, E. coli and E. faecalis (see the sensitivity table).
Razvoj rezistence za ciprofloksacin in druge fluorokinolone so opazili pri stafilokokih, zlasti pri S. aureus, P. aeruginosa, E. coli in E. faecalis, rezistentnimi na meticilin (glejte tabelo občutljivosti).
Especially patients undergoing long-term treatment (e. g. in cystic fibrosis, osteomyelitis), or patients who are extremely susceptible to infections (e. g. in selective prophylaxis in certain groups of neutropenic patients, artificial ventilation) show the highest risk.
Največje tveganje kažejo predvsem bolniki, pri katerih je zdravljenje dolgotrajno (npr. pri cistični fibrozi in osteomielitisu), ali bolnikih, ki so zelo dovzetni za okužbe (npr. pri selektivni profilaksi pri določeni skupini nevtropeničnih bolnikov, bolnikih na umetni ventilaciji).
- Enterobacteriaceae: ≤ 0.5 µg/ ml for susceptible, > 1 µg/ ml for resistant;
Enterobacteriaceae: ≤ 0, 5 µg/ ml za dovzetne, > 1 µg/ ml za rezistentne;
- Pseudomonas spp. ≤ 0.5 µg/ ml for susceptible, > 1 µg/ ml for resistant;
Pseudomonas spp. ≤ 0, 5 µg/ ml za dovzetne, > 1 µg/ ml za rezistentne;
- Acinetobacter spp. ≤ 1 µg/ ml for susceptible, > 1 µg/ ml for resistant;
Acinetobacter spp. ≤ 1 µg/ ml za dovzetne, > 1 µg/ ml za rezistentne;
- S. pneumonia ≤ 0.125 µg/ ml for susceptible, > 2 µg/ ml for resistant;
S. pneumonia ≤ 0, 125 µg/ ml za dovzetne, > 2 µg/ ml za rezistentne;
- Staphylococcus spp. ≤ 1 µg/ ml for susceptible, > 1 µg/ ml for resistant;
Staphylococcus spp. ≤ 1 µg/ ml za dovzetne, > 1 µg/ ml za rezistentne;
- H. influenza and M. catarrhalis ≤ 0.5 µg/ ml for susceptible, > 0.5 µg/ ml for resistant.
H. influenza in M. catarrhalis ≤ 0, 5 µg/ ml za dovzetne, > 0. 5 µg/ ml za rezistentne.
Non-species related breakpoints are ≤ 0,5 µg/ ml for susceptible, and > 1 µg/ ml for resistant organisms.
Mejne vrednosti, neodvisne od vrste, so ≤ 0, 5 µg/ ml za dovzetne in > 1 µg/ ml za rezistentne organizme.
Commonly susceptible species Gram-negative aerobe species Citrobacter spp.
Običajno dovzetne vrste Gramnegativne aerobne vrste Citrobacter spp.
Proteus mirabilis Proteus vulgaris Serratia liquefaciens Serratia marcescens Species for which acquired resistance may be a problem Gram-positive aerobes Coagulase-negative Staphylococcus Enterococcous faecalis MRSA* Staphylococcus aureus Staphylococcus aureus (methicillin susceptible) Streptococcus spp.
Staphylococcus aureus (dovzeten za meticilin) Streptococcus spp.
Streptoococus agalactiae Streptococcus pneumoniae S. pneumoniae PEN-R Streptococcus pyogenes Gram-negative aerobes Acinetobacter spp.
15 Streptoococus agalactiae Streptococcus pneumoniae S. pneumoniae PEN- R Streptococcus pyogenes Gramnegativni aerobi Acinetobacter spp.
Enterobacter aerogenes Enterobacter spp.
Enterobacter aerogenes Enterobacter spp. ki proizvaja Amp- C Escherichia coli Klebsiella pneumoniae Klebsiella oxytoca Pseudomonas aeruginosa Inherentno rezistentni organizmi Grampozitivni aerobi:
Amp-C producing Escherichia coli Klebsiella pneumoniae Klebsiella oxytoca Pseudomonas aeruginosa Inherently resistant organisms Gram-positive aerobes Enterococcus faecium Staphylococcus epidermidis Staphylococcus haemolyticus Gram-negative aerobes
Enterococcus faecium Staphylococcus epidermidis Staphylococcus haemolyticus Gramnegativni aerobi Multirezistentna E. coli Providencia spp.
Extended Spectrum Beta-lactamases MRSA:
ESBL: beta- laktamaze razširjenega spektra (Extended Spectrum Beta- lactamases).
Methicillin-resistant Staphylococcus aureus
Staphylococcus aureus, rezistenten na meticilin (Methicillin- resistant Staphylococcus aureus).
The peak plasma concentration is reached 0.5 - 2 hours after taking 50 - 1000 mg p. o. and varies from 0.3 - 5.9 mg/ l.
Največja koncentracija v plazmi je dosežena v 0, 5- 2 urah po peroralnem odmerku 50- 1000 mg, spreminja pa se od 0, 3 do 5, 9 mg/ l.
The bioavailability of ciprofloxacin after oral administration is between 70% and 85%.
Biološka uporabnost ciprofloksacina po peroralni uporabi je med 70 in 85%.
The bioavailability is lower if antacids that contain aluminium and/ or magnesium hydroxide, and calcium and iron salts are used concomitantly.
Biološka uporabnost je manjša ob sočasni uporabi antacidov, ki vsebujejo aluminijev in/ ali magnezijev hidroksid, ter kalcijevih ali železovih soli.
Twelve hours after i. v. administration of 200 mg the plasma concentration is still higher than the MIC values of the majority of clinically relevant pathogens (approximately 0.1 µg/ ml).
Dvanajst ur po intravenskem dajanju odmerka 200 mg je koncentracija v plazmi še vedno večja od najmanjše zaviralne koncentracije večine klinično pomembnih povzročiteljev (približno 0, 1 µg/ ml).
In steady-state conditions the apparent distribution volume of ciprofloxacin is situated between 1,7 and 2,7 l/ kg.
V pogojih ravnotežnega stanja je navidezni volumen porazdelitve ciprofloksacina med 1, 7 in 2, 7 l/ kg.
The ciprofloxacin concentration in the sputum consists of 50-70% of the serum concentration.
Koncentracija ciprofloksacina v sputumu je 50- 70% koncentracije v serumu.
The plasma protein binding of ciprofloxacin is situated between 16% and 28% and is not dependent on the concentration and pH (determined by means of ultrafiltration).
Vezava na beljakovine v plazmi je med 16 in 28% ter ni odvisna od koncentracije in vrednosti pH (določena z ultrafiltracijo).
Biotransformation:
16 Biološka transformacija:
Part of it is converted into desethylene-, sulpho-, oxo- and formylciprofloxacin.
Del učinkovine se pretvori v desetilen -, sulfo -, okso - in formilciprofloksacin.
77%.
Po peroralni uporabi se približno 70% ciprofloksacina izloči nespremenjenega, po intravenski pa približno 77%.
After oral administration 45% is excreted unchanged in the urine and 25% is excreted in the faeces.
Po peroralni uporabi se 45% izloči nespremenjenega v urinu, 25% pa v blatu.
After i. v. administration 62% is excreted unchanged in the urine and 15% is excreted in the faeces.
Po intravenski uporabi se 62% izloči nespremenjenega v urinu, 15% pa v blatu.
After oral administration 19% and after i. v. administration 12% of ciprofloxacin is excreted in the urine and faeces in the form of metabolites.
Po peroralni uporabi se 19%, po intravenski pa 12% ciprofloksacina izloči v urinu in blatu v obliki presnovkov.
The renal clearance constitutes 60%-70% of the total body clearance and is approximately 3 times higher than the creatinine clearance.
Ledvični očistek tvori 60– 70% skupnega očistka in je približno 3- krat večji od kreatininskega očistka.
The elimination half-life of ciprofloxacin after single or multiple oral dosage is between 3.4 and 6.9 hours.
Razpolovni čas izločanja ciprofloksacina po enkratnem ali večkratnem peroralnem odmerku je med 3, 4 in 6, 9 ur.
After single and multiple i. v. dosage the elimination half-life is between 3 – 4.6 hours.
Po enkratnih in večkratnih intravenskih odmerkih je razpolovni čas med 3 in 4, 6 ur.
16 Characteristics in patients:
Lastnosti pri bolnikih:
In patients with severely impaired renal function (creatinine clearance < 30 ml/ min) the elimination half-life may be prolonged by a factor of 2.
Pri bolnikih s hudo okvaro delovanja ledvic (kreatininski očistek < 30 ml/ min) je lahko razpolovni čas izločanja podaljšan za faktor 2.
Oral administration of 20 mg/ kg twice daily to children with cystic fibrosis gives an exposure that is comparable to that in adults following an oral dose of 750 mg twice daily.
Pri otrocih s cistično fibrozo je izpostavljenost po peroralnem odmerjanju 20 mg/ kg dvakrat na dan primerljiva z izpostavljenostjo pri odraslih po peroralnem odmerku 750 mg dvakrat na dan.
Lactic acid (E 270) Sodium chloride Hydrochloric acid (E 507) for pH adjustment Water for injections
Mlečna kislina (E 270) Natrijev klorid Klorovodikova kislina (E 507) za uravnavanje pH Voda za injekcije
Type I, clear glass vial, fitted with a chlorobutyl rubber stopper and aluminium flip-off caps.
Prozorna viala iz stekla vrste I z gumijastim zamaškom iz klorobutila in z aluminijastim pokrovom "flip- off".
1.5 10 or 20 vials.
1, 5, 10 ali 20 vial.
17 Use only clear solutions and undamaged containers.
Uporabite samo bistro raztopino in nepoškodovano ovojnino.
Any unused solution and the vial should be adequately disposed of, in accordance with local requirements.
Neuporabljeno raztopino in viale zavrzite v skladu z lokalnimi predpisi.